FDA Tells 23AndMe to Halt Marketing

December 11, 2013

  The Mountain View based 23AndMe, a personal genome service (PGS) that offers genome sequencing was ordered to stop marketing its service. The FDA report stated that 23AndMe did not demonstrate that they had “analytically or clinically validated the PGS for its intended uses” and the “FDA is concerned about the public health consequences of…
Read more